DAWN HARBATKIN: Open Payments
NPI 1033119284 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 34 payments from 19 companies in 2025. Trend: 2023 $473 · 2024 $5,052 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 2 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $120 |
| Braeburn Inc. | 3 | $117 |
| AstraZeneca Pharmaceuticals LP | 4 | $79 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| Janssen Pharmaceuticals, Inc | 2 | $34 |
| Averitas Pharma Inc. | 2 | $34 |
| EMD Serono, Inc. | 1 | $33 |
| Grifols USA, LLC | 1 | $31 |
| ITF Therapeutics LLC | 1 | $26 |
Products named: HYQVIA, BRIXADI, WAINUA, INGREZZA, SPRAVATO, QUTENZA, SUBLOCADE, Gamunex-C.
Industry payments across NY — which companies pay providers there.
